Kaplan–Meier analyses revealed that the high level of MYBL1 (p < 0.01, HR (95% CI) = 1.80 (1.22–2.37)), high CD31 staining (HR (p < 0.001, 95% CI) = 2.55 (1.96–3.14)) and grouped by both MYBL1 expression and CD31 staining (p < 0.01, HR (95% CI) = 2.55 (1.99–3.10)) were associated with reduced progression-free survival time in HCC patients (Fig. 1C). The gene discussed is MYBL1; the disease is hepatocellular carcinoma.